Analyzing Genetic Differences Between Sporadic Primary and Secondary/Tertiary Hyperparathyroidism by Targeted Next-Generation Panel Sequencing
Authors:
- 3 July 2021
- journal article
- research article
- Published by Springer Nature in Endocrine Pathology
- Vol. 32 (4) , 501-512
Abstract
Secondary hyperparathyroidism (SHPT) is characterized by excessive serum parathyroid hormone levels in response to decreasing kidney function, and tertiary hyperparathyroidism (THPT) is often the result of a long-standing SHPT. To date, several genes have been associated with the pathogenesis of primary hyperparathyroidism (PHPT). However, the molecular genetic mechanisms of uremic hyperparathyroidism (HPT) remain uncharacterized. To elucidate the differences in genetic alterations between PHPT and SHPT/THPT, the targeted next-generation sequencing of genes associated with HPT was performed using DNA extracted from parathyroid tissues. As a result, 26 variants in 19 PHPT or SHPT/THPT appeared as candidate pathogenic mutations, which corresponded to 9 (35%) nonsense, 8 (31%) frameshift, 6 (23%) missense, and 3 (11%) splice site mutations. The MEN1 (23%, 6/26), ASXL3 (15%, 4/26), EZH2 (12%, 3/26), and MTOR (8%, 2/26) genes were frequently mutated. Sixteen of 25 patients with PHPT (64%) had one or more mutations, whereas 3 (21%) of 21 patients with SHPT/THPT had only 1 mutation (p = 0.001). Sixteen of 28 patients (57%) with parathyroid adenoma (PA) had one or more mutations, whereas 3 of 18 patients (17%) with parathyroid hyperplasia (PH) had just one mutation (p = 0.003). Known driver mutations associated with parathyroid tumorigenesis such as CCND1/PRAD1, CDC73/HRPT2, and MEN1 were identified only in PA (44%, 7/16 with mutations). Our results suggest that molecular genetic abnormalities in SHPT/THPT are distinct from those in PHPT. These findings may help in analyzing the molecular pathogenesis underlying uremic HPT development.Keywords
This publication has 52 references indexed in Scilit:
- Germline and Somatic Mutations in Cyclin-Dependent Kinase Inhibitor Genes CDKN1A, CDKN2B, and CDKN2C in Sporadic Parathyroid AdenomasDiscover Oncology, 2013
- Identification of Somatic Mutations in Parathyroid Tumors Using Whole-Exome SequencingThe Journal of Clinical Endocrinology & Metabolism, 2012
- A unifying model for mTORC1-mediated regulation of mRNA translationNature, 2012
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylationBlood, 2011
- Detection of nonneutral substitution rates on mammalian phylogeniesGenome Research, 2009
- Secondary and Tertiary Hyperparathyroidism, State of the Art Surgical ManagementSurgical Clinics of North America, 2009
- In silico analysis of missense substitutions using sequence-alignment based methodsHuman Mutation, 2008
- Mutational analysis of CDKN1B, a candidate tumor-suppressor gene, in refractory secondary/tertiary hyperparathyroidismKidney International, 2008
- HRPT2, encoding parafibromin, is mutated in hyperparathyroidism–jaw tumor syndromeNature Genetics, 2002
- Clonal Chromosomal Defects in the Molecular Pathogenesis of Refractory Hyperparathyroidism of UremiaJournal of the American Society of Nephrology, 2002